Literature DB >> 34668064

Anticoagulation in patients with acute kidney injury undergoing kidney replacement therapy.

Rupesh Raina1,2, Ronith Chakraborty3,4, Andrew Davenport5, Patrick Brophy6, Sidharth Sethi7, Mignon McCulloch8, Timothy Bunchman9, Hui Kim Yap10,11.   

Abstract

Kidney replacement therapy (KRT) is used to provide supportive therapy for critically ill patients with severe acute kidney injury and various other non-renal indications. Modalities of KRT include continuous KRT (CKRT), intermittent hemodialysis (HD), and sustained low efficiency daily dialysis (SLED). However, circuit clotting is a major complication that has been investigated extensively. Extracorporeal circuit clotting can cause reduction in solute clearances and can cause blood loss, leading to an upsurge in treatment costs and a rise in workload intensity. In this educational review, we discuss the pathophysiology of the clotting cascade within an extracorporeal circuit and the use of various types of anticoagulant methods in various pediatric KRT modalities.
© 2021. IPNA.

Entities:  

Keywords:  Anticoagulation; Argatroban; Citrate; Heparin; Hirudin; Kidney replacement therapy; Prostacyclin

Mesh:

Substances:

Year:  2021        PMID: 34668064     DOI: 10.1007/s00467-021-05020-z

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.651


  90 in total

1.  Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients.

Authors:  R L Mehta; B R McDonald; M M Aguilar; D M Ward
Journal:  Kidney Int       Date:  1990-11       Impact factor: 10.612

2.  Treatment of metabolic alkalosis during continuous renal replacement therapy with regional citrate anticoagulation.

Authors:  D Kindgen-Milles; J Amman; W Kleinekofort; S Morgera
Journal:  Int J Artif Organs       Date:  2008-04       Impact factor: 1.595

3.  Continuous venovenous haemofiltration using polyacrylonitrile filters does not activate contact system and intrinsic coagulation pathways.

Authors:  J Salmon; R Cardigan; I Mackie; S L Cohen; S Machin; M Singer
Journal:  Intensive Care Med       Date:  1997-01       Impact factor: 17.440

4.  Sodium citrate 4% locking solution for central venous dialysis catheters--an effective, more cost-efficient alternative to heparin.

Authors:  Linda Grudzinski; Patricia Quinan; Sophie Kwok; Andreas Pierratos
Journal:  Nephrol Dial Transplant       Date:  2006-10-25       Impact factor: 5.992

5.  Role of contact system activation in hemodialyzer-induced thrombogenicity.

Authors:  R D Frank; J Weber; H Dresbach; H Thelen; C Weiss; J Floege
Journal:  Kidney Int       Date:  2001-11       Impact factor: 10.612

6.  Anticoagulation options for pediatric hemodialysis.

Authors:  Andrew Davenport
Journal:  Hemodial Int       Date:  2003-04-01       Impact factor: 1.812

Review 7.  Renal replacement therapy and anticoagulation.

Authors:  Timo Brandenburger; Thomas Dimski; Torsten Slowinski; Detlef Kindgen-Milles
Journal:  Best Pract Res Clin Anaesthesiol       Date:  2017-08-24

Review 8.  Alternatives to standard unfractionated heparin for pediatric hemodialysis treatments.

Authors:  Andrew Davenport
Journal:  Pediatr Nephrol       Date:  2012-02-29       Impact factor: 3.714

9.  Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit.

Authors:  Andrew Davenport; Ashita Tolwani
Journal:  NDT Plus       Date:  2009-09-25

Review 10.  Clinical review: Patency of the circuit in continuous renal replacement therapy.

Authors:  Michael Joannidis; Heleen M Oudemans-van Straaten
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.